LIVE

ROIV

Roivant Sciences Ltd.

ROIV

NASDAQ·Healthcare·Biotechnology·Mkt cap $25.2B

$34.67

▼ -1.03%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$10.71 - $35.90

P/E

—

Fwd P/E

-29.31

Beta

1.14

Div Yield

0.00%

Avg Vol

5.9M

Shares Out

—

Mkt Cap

$25.2B

Price action

Price chart

Up 219.3% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

No bull reasons captured for this rating yet.

▼

Bear Case

1 risk

  • Average volatility.

Growth

Revenue decline expected

Value

Deep value opportunity - significant discount to sector peers

Momentum

Hot

+23.6% over 3m

Quality

Excellent

Below average quality

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Jul 1, 2026

“
Q2 26 RECAP

MAY 20, 2026

Reported EPS of -$0.36 vs -$0.29 consensus (-24.4% surprise). Revenue of $2.5M vs $3.4M expected (-26.2%).

EPS miss
Revenue miss

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-24.4%

Next: Jul 1, 2026

Wall Street consensus

5 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

5

100%

Hold

0%

Sell

0%

Median Price Target

$40.50

▲ +16.8% vs $34.67

Low $36.00
Median $40.50
High $42.00

Latest: Guggenheim · $36.00 · May 26, 2026

4 analysts covering

View full analyst page →

vs Industry

How ROIV stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.

Related

Peers & themes

Peers

No peer data available.

Themes

No themes assigned.